Fimasartan
- Generic Name
- Fimasartan
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H31N7OS
- CAS Number
- 247257-48-3
- Unique Ingredient Identifier
- P58222188P
- Background
Fimasartan is an angiotensin II receptor antagonist (ARB) drug employed in the treatment of both hypertension and heart failure. It has been found to be safe when administered with hydrochlorothiazide (a diuretic) in clinical trials. Fimasartan was initially approved September 9th, 2010 in South Korea and is marketed under the brand name Kanarb by Boryung Pharmaceuticals.
- Indication
Used for the treatment of hypertension and heart failure .
- Associated Conditions
- Hypertension, Essential Hypertension
- Associated Therapies
- -
A Study to Assess Food Effect on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers
- First Posted Date
- 2009-11-04
- Last Posted Date
- 2009-12-24
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 24
- Registration Number
- NCT01007409
A Study to Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers
- First Posted Date
- 2009-10-08
- Last Posted Date
- 2009-10-08
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 28
- Registration Number
- NCT00991705
Study to Compare and Assess the Safety and Pharmacokinetic Characteristics After Oral Administration of Fimasartan (BR-A-657βK) in Healthy Elderly and Young Male Volunteers
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2009-11-04
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 22
- Registration Number
- NCT00937534
A Study to Evaluate the Pharmacokinetic Drug Interaction After Oral Concurrent Administration of Fimasartan and Amlodipine in Healthy Male Volunteers
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2009-10-08
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 34
- Registration Number
- NCT00938197
- Locations
- π°π·
Seoul National University Hospital, Seoul, Korea, Republic of
Antihypertensive Efficacy and Tolerability and Determine the Adequate Antihypertensive Dosage of Fimasartan in Mild to Moderate Essential Hypertension Patients
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2009-06-18
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 182
- Registration Number
- NCT00923611
- Locations
- π°π·
Seoul National University Hospital, Seoul, Korea, Republic of
A Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Fimasartan and Hydrochlorothiazide in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2009-10-08
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 34
- Registration Number
- NCT00923533
Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension Patients
- First Posted Date
- 2009-06-17
- Last Posted Date
- 2018-04-10
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 506
- Registration Number
- NCT00922480
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath